Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

177Lu-PSMA-617 (Pluvicto) for the Treatment of Patients With Progressive PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Super Scan Bone Scan

NCT06972628 is registered in ClinicalTrials.gov with Ebrahim S Delpassand as lead sponsor.

NCT NCT06972628
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06972628 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
177Lu-PSMA-617 (Pluvicto) for the Treatment of Patients With Progressive PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Super Scan Bone Scan
Lead sponsor
Ebrahim S Delpassand
Phase
Phase 2
Overall status
Recruiting
Start date
May 23, 2025
Completion date
April 1, 2029
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic castration-resistant prostate cancer, prostate cancer, prostate cancer (crpc), prostate cancer metastatic, prostate cancer patients with bone metastasis